Aura Biosciences (AURA) Expected to Release Earnings on Thursday

Aura Biosciences (NASDAQ:AURA) is anticipated to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.3681) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.10). On average, analysts expect Aura Biosciences to post ($1.61) EPS for the current fiscal year and ($1.39) EPS for the next fiscal year.

Aura Biosciences Price Performance

Shares of NASDAQ AURA traded up $0.17 during mid-day trading on Tuesday, reaching $6.21. 244,239 shares of the company’s stock traded hands, compared to its average volume of 562,824. The stock has a market cap of $643.49 million, a P/E ratio of -3.55 and a beta of 0.41. The business has a 50-day simple moving average of $6.64 and a 200 day simple moving average of $6.70. Aura Biosciences has a 1-year low of $4.73 and a 1-year high of $9.53.

Analysts Set New Price Targets

A number of research firms recently weighed in on AURA. Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, October 12th. Wall Street Zen downgraded Aura Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, HC Wainwright decreased their price objective on Aura Biosciences from $24.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $17.50.

About Aura Biosciences

Aura Biosciences, Inc (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.